AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Linda Loyd
PHILADELPHIA _ Scientists said Monday that an experimental vaccine that may be the first to fight a virus linked to cervical cancer was highly effective in reducing the risk of infections and precancerous lesions in women studied over four years.
The vaccine, developed by Merck & Co. Inc. at its West Point research center outside Philadelphia, was 94 percent effective in protecting women from infection against one human papilloma virus _ HPV type 16 _ believed responsible for half of all cervical cancers, according to a study presented Monday at a medical conference in Washington.
The experimental inoculation was 100 percent effective in protecting 755 women who received the vaccine from developing precancerous cervical lesions during four years, researchers said.
Although there are still hurdles, the news marks a sign of progress against an illness that kills about 225,000 women a year, some 5,000 of them in the United States.…
Source: HighBeam Research, Merck reports good results on cervical cancer vaccine.